Simultaneous measurement of cell lineage and cell fates is a longstanding goal in biomedicine. Here we describe EMBLEM, a strategy to track cell lineage using endogenous mitochondrial DNA variants in ATAC-seq data. We show that somatic mutations in mitochondrial DNA can reconstruct cell lineage relationships at single cell resolution with high sensitivity and specificity. Using EMBLEM, we define the genetic and epigenomic clonal evolution of hematopoietic stem cells and their progenies in patients with acute myeloid leukemia. EMBLEM extends lineage tracing to any eukaryotic organism without genetic engineering.
2 reconstruction of cell lineage relationships in model organisms, and has been coupled with transcriptome profiling to inform cell fates 2 . These prospective "mutate-and-record" methods provide powerful tools to resolve the developmental origin of cells in genetically engineered cells and organisms, but cannot be utilized in living humans, archival clinical samples, or any wild type organism 1 . Given these limitations, retrospective lineage tracing using endogenous genetic markers is an alternative solution. Recent advances in sequencing enable naturally occurring somatic mutations to be used as lineage markers, which usually required single-cell genome sequencing to capture the sparse genetic information 3, 4 . Regions with high mutation rates, such as microsatellite repeats, retrotransposons, and copy-number variants, has been used to resolve the lineage relationship for normal or cancerous tissue samples 5, 6 . These methods reduce the cost of whole genome sequencing, but still lack information on cell phenotypes. Simultaneous measurement of the lineage relationship and cell fates is ultimately required to address many biomedical questions. Here we describe EMBLEM (Epigenome and Mitochondrial Barcode of Lineage from Endogenous Mutations), a strategy to track cell lineage using endogenous mitochondrial DNA variants in ATACseq data. The end result of EMBLEM is single-cell lineage information and rich global epigenomic profile from the same individual cells ( Fig.1a and Supplementary Figs. 1) .
Assay of Transposase-Accessible Chromatin by sequencing (ATAC-seq) is a sensitive method used to study chromatin accessibility profiles in diverse cell types and organisms 7 . During DNA transposition and amplification in cells, mitochondrial DNA is also amplified at the same time ( Fig. 1a) . Mitochondrial DNA (mtDNA) is a ~16kb circular genome with ~10-fold higher mutation rate compared to the nuclear genome.
Hence, mtDNA incrementally accumulates unique, irreversible genetic mutations that are passed on to daughter cells even in healthy humans and may be used for lineage tracing 8, 9 . The majority of somatic mtDNA mutations are noncoding and thought to be passenger 10 . Importantly, the number of mitochondria (and therefore mtDNA) range from several hundreds to >10,000 per cell in different cell types, facilitating robust mtDNA analysis even from a single cell.
We first observed that ATAC-seq effectively enriches for mtDNA. While mtDNA is present in many kinds of DNA sequence libraries, it is substantially enriched in ATACseq libraries due to the fact that mtDNA is not chromatinized and is therefore highly accessible. ATAC-seq enables a 17-fold or greater enrichment of mtDNA compared to exome sequencing or whole genome sequencing in GM12878 human B cells ( Fig. 1b) , leading to an average ~18,000X coverage of mtDNA (Supplementary Figs. 2a) . With this coverage, we detected 27 mitochondrial variants from GM12878 cells ( Fig. 1c ). 13 of these variants have a variant allele frequency (VAF) greater than 90%, which are known as homoplasmic variants (Supplementary Figs. 2b) . We also detected 14 low frequency mitochondrial DNA variants, with VAFs ranging from 0.1% to 24% (Fig. 1c) .
The VAF from bulk ATAC-seq data represents the average of the allele frequencies of the cell population. A 25% VAF may arise from 25% of cells in the population with a homoplasmic variant, or alternatively arise from 100% of cells all having a quarter of their mitochondria with the variant allele ( Fig. 1d) . To distinguish between these two models, we analyzed single-cell ATAC-seq data from GM12878.
For 4 mtDNA variants (VAF between 0.5%~24% at population level), we find that a mixture of both models is in action for different variants (Fig. 1e) . For instance, mtDNA mutation 3082 is widely spread among single cells, but at low frequency per cell.
Because it is extremely unlikely (see METHOD) that the identical mutation arose independently in every single cell, cells sharing the same mitochondrial mutations are inferred to have descended from the same ancestral cell. These results suggest that even low frequency heteroplasmic mtDNA mutations can be exploited for lineage tracing.
To prove the principle that somatic mitochondrial mutations can track cells from the same ancestor and to quantify the power of this technique, we next applied EMBLEM to primary blood cells from patients with acute myeloid leukemia (AML).
Human AML is organized as a hierarchy: A hematopoietic stem cell suffers an initiating mutation in a small number of chromatin modifier genes, and is termed the pre-leukemic hematopoietic stem cell (pHSC). pHSCs are not able transplant AML, but upon
accumulation of additional mutations, they give rise to leukemic stem cells (LSCs) that are able to self-renew and recapitulate AML disease upon transplantation 11, 12 . Finally, LSCs give rise to the bulk leukemic blast cells in AML 12 . Targeted exome sequencing in these same samples have identified clonal mutations in tumor suppressor genes and oncogenes that link the lineage relationship of LSCs and blasts, providing the ground truth for our analyses 13 .
We applied EMBLEM to the ATAC-seq profiles of FACS-purified pHSC, LSCs and leukemic blasts that we previously reported 14 . We first detected heteroplasmic variants from bulk ATAC-seq and then investigated whether the variants exist in each single cell using single-cell ATAC-seq. We found the LSC and blast populations not only shared the same heteroplasmic variants, but also showed similar distribution and allele frequency at the cellular level ( Supplementary Figs. 3) . These results indicate the two population are identical at the genetic level, but divergent at the epigenomic level which has been shown in previous studies 14, 15 . In patient SU353, we identified four diagnostic mtDNA mutations in the same cell ( Fig. 1f) , which indicates these four mitochondrial variants already co-existed in the ancestral cell (see METHOD). With the assumption that all these LSCs and blasts are clonal, we further quantified the detection rate of each mtDNA variant as a function of allele frequency and sequencing depth ( Fig.   1g ). We found that when a single variant allele has a frequency greater than 20%, the detection rate can be up to 90% with >20X coverage (e.g. site 6776). In contrast, when the variant allele has a frequency lower than 1%, the detection rate drops to 20% when the coverage is below 100X (e.g. site 6705). While high drop-out rate is a common challenge for single-cell technologies 16 , computational imputation of the missing information from single cell data can address this problem 17 . When multiple mtDNA variants are co-detected in multiple single cells, we can infer their origin and linkage in the ancestral cell (see METHOD). Thus, cells containing any one of these variants will still inform their origin from the same lineage. With any combination of the four variants, 90% (sensitivity) of the cells can be unambiguously assigned to the correct lineage with just 20x mtDNA coverage ( Fig. 1h) . Similar performance of single cell lineage tracing for another patient (SU070) are shown in Supplementary Figs. 4. These results
demonstrate that somatic DNA mutations in the mitochondrial genome are a powerful endogenous marker to identify clonal cell populations.
To expand on these findings to additional different cell lineages, we applied EMBLEM to bulk ATAC-seq data from sorted blood cells from 9 healthy human donors and 11 patients with AML 14 . We identified homoplasmic and heteroplasmic mtDNA mutations in multiple lineages of primary blood cells from healthy donors and all AML patients ( Fig. 2a and Supplementary Figs. 5a) . The homoplasmic variants from each patient depicted the phylogenetic relationship of individuals, permitting identification of cells from individual patients on the basis of mtDNA variants (Fig. 2a ). The heteroplasmic mutations shows a similar mutant spectrum as observed by previous studies using cancer genomic data (Supplementary Figs. 5b and c) 10 . Furthermore, the heteroplasmic mtDNA mutations within each patient revealed the lineage relationship between FACS-sorted cell populations ( Fig. 2b-c) . In all AML cases with LSCs examined(6 cases), the LSCs and their corresponding leukemic blasts have nearly identical heteroplasmic mtDNA mutations (Supplementary Figs. 5d- 
suggesting a direct lineage relationship and short generation history between LSCs and blasts. We then examined whether any of the mtDNA variants present in LSCs can be seen in the pHSCs, where the first leukemia-associated protein-coding mutations have already occurred in functional normal hematopoietic stem cells 13, 14 . We detected LSCassociated mtDNA mutations in pHSCs in all 11 cases. Interestingly in 7 of the 11 cases, we also detected additional heteroplasmic mtDNA mutations present only in pHSCs ( Supplementary Figs. 5g-h) . pHSCs are capable of long-term self-renewal and possess a clonal growth advantage, allowing them to clonally outcompete normal HSCs.
Indeed, the clonal frequency of pHSCs is a poor prognostic factor for overall survival in AML 14 . Our discovery of pHSCs with distinct heteroplasmic mtDNA mutations suggests the existence of multiple distinct sub-clones of pHSCs in AML patients.
To validate the heterogeneity of pHSCs inferred from EMBLEM of bulk cell populations, we performed single-cell ATAC-seq of HSCs from AML patient SU353, which exhibited both a high burden of pre-leukemic somatic coding gene mutations and
high frequency of pHSC-specific heteroplasmic mtDNA mutations 14 . We identified the heteroplasmic mtDNA variants from each single cell, which separated the HSCs into three lineages: Two clonal subpopulations termed "clone 1" (18 cells) and "clone 2"
(104 cells), and a third population with no mtDNA variants despite sufficient mtDNA coverage (WT, 31 cells) ( Fig. 2d) . Notably, clone 2 possessed pHSC-specific mtDNA mutations, while clone 1 possessed mtDNA mutations shared with LSCs, indicating clone1 is the lineage precursor of AML. These results confirm that multiple pHSC clones arise in AML patients, and one subclone eventually evolved to become the LSC.
Finally, we related the clonotype of pHSCs to their single-cell chromatin accessibility profiles. We interrogated the patterns of active DNA elements and enriched transcription factor motifs in sequential stages of AML development from the same patient, and contrasted with HSCs from normal donors using ChromVAR 15 ( Fig. 2e and   Supplementary Figs. 6a) . The chromatin accessibility profiles of pHSCs are more similar to HSCs than to LSCs or leukemic blasts. The greatest deviation between HSC and other cell types occurred at DNA binding motifs of the transcription factor Jun/Fos, a known key regulator of HSC biology 18 (Fig. 2f) . Furthermore, the three lineages of pHSCs revealed by mtDNA mutations also showed distinctive chromatin profiles (Fig.   2g ). Clone 1 pHSC, which gives rise to the LSC and AML leukemia, is already more similar to LSCs and blasts in its chromatin accessibility. In contrast, clone 2 that comprises the larger fraction of pHSCs exhibited variable chromatin profiles at the single-cell level that spanned the range of normal HSCs. Thus both lineage tracing and single cell epigenomic states suggest clone 1 as the original stem cell of the AML in patient SU353. Supervised comparison of the chromatin accessibility profiles among these clonal sub-populations further identified distinct and significantly enriched transcription factor motifs ( Fig. 2h, Supplementary Figs.6b-d) . These results indicate the heterogeneity of HSCs from AML patients both on a genetic and epigenomic level.
This pilot study provides a practical approach to clarify the process of pre-leukemic clonal evolution and informs the emerging biology of clonal hematopoiesis.
X u e t a l .
In summary, we present a computational strategy by which we can trace cell lineage by endogenous mtDNA mutations and combine chromatin accessibility profiling in the same cell using ATAC-seq data. This approach is applicable to any eukaryote, does not require genetic engineering or genome editing, and is cost effective as the lineage information comes "for free" on top of epigenomic insights. EMBLEM may also be extended to other single cell technologies, in which mtDNA is sequenced. We show that EMBLEM is successful even with low frequency heteroplasmic mutations, detection of rare clones in a population, and authentic clinical samples. Potential limitations to this approach include instances of biased mtDNA replication and segregation and rare inter-cellular transfer of mitochondria 19 . With advances in the throughput and depth of single-cell genomic technologies, we believe EMBLEM may be a powerful tool to bring insight for many biomedical questions, including development, regeneration, immunity, and cancer.
Methods
Methods, including statement of data availability and any associated accession code and reference, as available online.
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